Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer?
Introduction: Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology patients. There are no accurate risk assessment tools to predict venous thromboembolism (VTE). Circulating tumor cells (CTCs), circulating tumor microemboli (CTM), and high platelet-lymphocyte ra...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2022-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | https://www.brazilianjournalofoncology.com.br/details/212/en-US/is-platelet-lymphocyte-ratio--plr--a-predictor-of-thrombosis-and-together-with-circulating-tumor-cells-capable-to-determine-recurrence-free-survival-i |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850249775912321024 |
|---|---|
| author | Bruno Soriano Pignataro Emne Ali Abdallah Celso Abdon Lopes Mello Vinicius Fernando Calsavara Kenji Nishinari Anna Paula Carreta Ruano Marcello F. Fanelli Guilherme Yazbek Ludmilla Thomé Domingos Chinen |
| author_facet | Bruno Soriano Pignataro Emne Ali Abdallah Celso Abdon Lopes Mello Vinicius Fernando Calsavara Kenji Nishinari Anna Paula Carreta Ruano Marcello F. Fanelli Guilherme Yazbek Ludmilla Thomé Domingos Chinen |
| author_sort | Bruno Soriano Pignataro |
| collection | DOAJ |
| description | Introduction: Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology patients. There are no accurate risk assessment tools to predict venous thromboembolism (VTE). Circulating tumor cells (CTCs), circulating tumor microemboli (CTM), and high platelet-lymphocyte ratio (PLR) may predispose to VTE. Objective: To evaluate correlations of CTCs, CTM, and PLR with VTE and recurrence-free survival (RFS) in gastric cancer patients. Material and Methods: Patients with gastric cancer (localized and metastatic disease) were recruited (March 2016 to April 2017). CTCs were analysed by ISET at two timepoints: before neoadjuvant treatment (CTC1) and after surgery/before adjuvant therapy (CTC2) for patients with localized disease, and before first-line chemotherapy (CTC1) and after 6 months (CTC2) for patients with metastases. VTE incidence was determined retrospectively. RFS was estimated by Kaplan-Meier analysis. Results: We evaluated 93 patients. According to Khorana scores, 63 (67.7%) patients were at intermediate and 30 (32.3%) were at high risk for VTE. VTE incidence was 20.4% and CTM were found in 39.8%. VTE developed in 7/37 (18.9%) CTM-positive and in 11/50 (22%) CTM-negative patients (p=0.93). When PLR >288, VTE occurred in 7/14 patients (p=0.005). PLR also associated with poor RFS (p<0.0001). CTC2 was associated with poor RFS (p<0.0001). CTC2, PLR and VTE were independent prognostic factors for RFS (p=0.005, 0.043, and <0.0001, respectively). Conclusion: PLR is a prognostic indicator for VTE and RFS in gastric cancer patients. Neither CTC, nor CTM improved risk stratification for VTE in our studied population. PLR, CTC2, and VTE were independent prognostic factors for RFS. |
| format | Article |
| id | doaj-art-8a8bfc707ebf4972a51140deffa68463 |
| institution | OA Journals |
| issn | 2526-8732 |
| language | English |
| publishDate | 2022-10-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-8a8bfc707ebf4972a51140deffa684632025-08-20T01:58:27ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322022-10-01180010.5935/2526-8732.20220350Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer?Bruno Soriano Pignataro0Emne Ali Abdallah1Celso Abdon Lopes Mello2Vinicius Fernando Calsavara3Kenji Nishinari4Anna Paula Carreta Ruano5https://orcid.org/0000-0001-7793-6032Marcello F. Fanelli6Guilherme Yazbek7Ludmilla Thomé Domingos Chinen8Departament of Vascular and Endovascular Surgery, A.C. Camargo Cancer Center, BrazilIQVIA, São Paulo, BrazilDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, BrazilSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USADepartament of Vascular and Endovascular Surgery, A.C. Camargo Cancer Center, BrazilDepartment of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, BrazilOncologia Clínica da Rede São Camilo, São Paulo, BrazilDepartament of Vascular and Endovascular Surgery, A.C. Camargo Cancer Center, BrazilNúcleo de Ensino e Pesquisa da Rede São Camilo, São Paulo, BrazilIntroduction: Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in oncology patients. There are no accurate risk assessment tools to predict venous thromboembolism (VTE). Circulating tumor cells (CTCs), circulating tumor microemboli (CTM), and high platelet-lymphocyte ratio (PLR) may predispose to VTE. Objective: To evaluate correlations of CTCs, CTM, and PLR with VTE and recurrence-free survival (RFS) in gastric cancer patients. Material and Methods: Patients with gastric cancer (localized and metastatic disease) were recruited (March 2016 to April 2017). CTCs were analysed by ISET at two timepoints: before neoadjuvant treatment (CTC1) and after surgery/before adjuvant therapy (CTC2) for patients with localized disease, and before first-line chemotherapy (CTC1) and after 6 months (CTC2) for patients with metastases. VTE incidence was determined retrospectively. RFS was estimated by Kaplan-Meier analysis. Results: We evaluated 93 patients. According to Khorana scores, 63 (67.7%) patients were at intermediate and 30 (32.3%) were at high risk for VTE. VTE incidence was 20.4% and CTM were found in 39.8%. VTE developed in 7/37 (18.9%) CTM-positive and in 11/50 (22%) CTM-negative patients (p=0.93). When PLR >288, VTE occurred in 7/14 patients (p=0.005). PLR also associated with poor RFS (p<0.0001). CTC2 was associated with poor RFS (p<0.0001). CTC2, PLR and VTE were independent prognostic factors for RFS (p=0.005, 0.043, and <0.0001, respectively). Conclusion: PLR is a prognostic indicator for VTE and RFS in gastric cancer patients. Neither CTC, nor CTM improved risk stratification for VTE in our studied population. PLR, CTC2, and VTE were independent prognostic factors for RFS.https://www.brazilianjournalofoncology.com.br/details/212/en-US/is-platelet-lymphocyte-ratio--plr--a-predictor-of-thrombosis-and-together-with-circulating-tumor-cells-capable-to-determine-recurrence-free-survival-iplatelet-lymphocyte ratiocirculating tumor cellscirculating tumor microembolithrombosisgastric cancer |
| spellingShingle | Bruno Soriano Pignataro Emne Ali Abdallah Celso Abdon Lopes Mello Vinicius Fernando Calsavara Kenji Nishinari Anna Paula Carreta Ruano Marcello F. Fanelli Guilherme Yazbek Ludmilla Thomé Domingos Chinen Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer? Brazilian Journal of Oncology platelet-lymphocyte ratio circulating tumor cells circulating tumor microemboli thrombosis gastric cancer |
| title | Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer? |
| title_full | Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer? |
| title_fullStr | Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer? |
| title_full_unstemmed | Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer? |
| title_short | Is platelet-lymphocyte ratio (PLR) a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence-free survival in patients with gastric cancer? |
| title_sort | is platelet lymphocyte ratio plr a predictor of thrombosis and together with circulating tumor cells capable to determine recurrence free survival in patients with gastric cancer |
| topic | platelet-lymphocyte ratio circulating tumor cells circulating tumor microemboli thrombosis gastric cancer |
| url | https://www.brazilianjournalofoncology.com.br/details/212/en-US/is-platelet-lymphocyte-ratio--plr--a-predictor-of-thrombosis-and-together-with-circulating-tumor-cells-capable-to-determine-recurrence-free-survival-i |
| work_keys_str_mv | AT brunosorianopignataro isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT emnealiabdallah isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT celsoabdonlopesmello isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT viniciusfernandocalsavara isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT kenjinishinari isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT annapaulacarretaruano isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT marcelloffanelli isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT guilhermeyazbek isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer AT ludmillathomedomingoschinen isplateletlymphocyteratioplrapredictorofthrombosisandtogetherwithcirculatingtumorcellscapabletodeterminerecurrencefreesurvivalinpatientswithgastriccancer |